<DOC>
	<DOC>NCT00451386</DOC>
	<brief_summary>This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.</brief_summary>
	<brief_title>Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Patients with UTI must have white blood cells and bacteria in the urine with bladder catheterization or urologic abnormality, kidney infection or both Patients with SSTI must have a recent infection Patients with CAP must have a chest xray indicating bacterial pneumonia and a fever Patients with complete urinary tract blockage or kidney abscess Patients with infected burn wounds, bone infection, or bacterial arthritis Patients on mechanical ventilation or those with cystic fibrosis, chronic lung disease or puss in the space between the chest wall and lung</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>